secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001750284-25-000007
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2
--------------------------------------------------------------------------------

- Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
- Study planned for approximately 35 patients with initiation anticipated in H2 2025.
- Results to inform potential Phase 3 pivotal trial in frontline metastatic setting.
- Olema retains full global commercial and marketing rights to palazestrant; Pfizer supplies atirmociclib.
- This is Olema’s second clinical trial agreement with Pfizer; prior agreement from Nov 2020 for palazestrant + palbociclib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/0001750284-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/olma-20250902.htm
  HTML page:      https://secwatch.observer/filing/0001750284-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer